Passive immunization against congenital cytomegalovirus infection: Current state of knowledge

Pharmacology

Volumn 95, Issue 5-6, 2015, Pages 209-217

  Jückstock, Julia ^a   Rothenburger, Markus ^b   Friese, Klaus ^a   Traunmüller, Friederike ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b BIOTEST AG   (Germany)

^c J & P Medical Research Ltd   (Austria)

Author keywords

Betaherpesvirus; Fetal sonographic anomalies; Hearing deficit; Immune globulin therapy; Sensorineural sequelae; Seroconversion

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO; CYTOMEGALOVIRUS-SPECIFIC HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN;

ANAPHYLAXIS; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ASEPTIC MENINGITIS; CEREBRAL PALSY; CHILL; CONGENITAL CYTOMEGALOVIRUS INFECTION; CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EPIDEMIOLOGICAL DATA; EPILEPSY; FEVER; FLU LIKE SYNDROME; HEARING IMPAIRMENT; HEMOLYSIS; HOT FLUSH; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMORAL IMMUNITY; IN VITRO STUDY; INFECTION PREVENTION; INTRAUTERINE GROWTH RETARDATION; KIDNEY FAILURE; KNOWLEDGE; MALAISE; MENTAL DEFICIENCY; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PLACENTA DISORDER; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINFECTION; REVIEW; SEROCONVERSION; TENSION HEADACHE; THROMBOEMBOLISM; VERTICAL TRANSMISSION; VIREMIA; VIRUS CELL INTERACTION; VIRUS DIAGNOSIS; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS TRANSMISSION; VISUAL DISORDER; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; PATHOGENICITY; PREVENTION AND CONTROL; TRANSMISSION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY;

EID: 84928731869     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000381626     Document Type: Review

References (85)

1. Landolfo S, Gariglio M, Gribaudo G, Lembo D: The human cytomegalovirus. Pharmacol Ther 2003; 98: 269-297
2. Britt W: Virus entry into host, establishment of infection, spread in host, mechanisms of tissue damage; in Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (eds): Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge, Cambridge University Press, 2007, chapter 41
3. Gerna G, Baldanti F, Revello MG: Pathogenesis of human cytomegalovirus infection and cellular targets. Hum Immunol 2004; 65: 381-386
4. Fisher S, Genbacev O, Maidji E, Pereira L: Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. J Virol 2000; 74: 6808-6820
5. Cheeran MC, Hu S, Ni HT, Sheng W, Palmquist JM, Peterson PK, Lokensgard JR: Neural precursor cell susceptibility to human cytomegalovirus diverges along glial or neuronal differentiation pathways. J Neurosci Res 2005; 82: 839-850
6. Jones CA: Congenital cytomegalovirus infection. Curr Probl Pediatr Adolesc Health Care 2003; 33: 70-93
7. Cannon MJ: Congenital cytomegalovirus (CMV) epidemiology and awareness. J Clin Virol 2009; 46(suppl 4): S6-S10
8. Dollard SC, Grosse SD, Ross DS: New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007; 17: 355-363
9. Kenneson A, Cannon MJ: Review and metaanalysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17: 253-276
10. Bodéus M, Kabamba-Mukadi B, Zech F, Hubinont C, Bernard P, Goubau P: Human cytomegalovirus in utero transmission: follow-up of 524 maternal seroconversions. J Clin Virol 2010; 47: 201-202
11. Adler SP: Screening for cytomegalovirus during pregnancy. Infect Dis Obstet Gynecol 2011; 2011: 1-9
12. Enders G, Daiminger A, Bäder U, Exler S, Enders M: Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 2011; 52: 244-246
13. Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA: Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J 1992; 11: 93-99
14. Fowler KB, Dahle AJ, Boppana SB, Pass RF: Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?. J Pediatr 1999; 135: 60-64
15. Cannon MJ, Davis KF: Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health 2005; 5: 70
16. Adler SP, Finney JW, Manganello AM, Best AM: Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J Pediatr 2004; 145: 485-491
17. Harvey J, Dennis CL: Hygiene interventions for prevention of cytomegalovirus infection among childbearing women: systematic review. J Adv Nurs 2008; 63: 440-450
18. Vauloup-Fellous C, Picone O, Cordier AG, Parent-du-Châtelet I, Senat MV, Frydman R, Grangeot-Keros L: Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy?. Results of a 3-year prospective study in a French hospital. J Clin Virol 2009; 46(suppl 4): S49-S53
19. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK: The silent global burden of congenital cytomegalovirus. Clin Microbiol Rev 2013; 26: 86-102
20. Jeon J, Victor M, Adler SP, Arwady A, Demmler G, Fowler K, Goldfarb J, Keyserling H, Massoudi M, Richards K, Staras SA, Cannon MJ: Knowledge and awareness of congenital cytomegalovirus among women. Infect Dis Obstet Gynecol 2006; 2006: 80383
21. Ross DS, Victor M, Sumartojo E, Cannon MJ: Women s knowledge of congenital cytomegalovirus: results from the 2005 HealthStyles survey. J Womens Health (Larchmt) 2008; 17: 849-858
22. Centers for Disease Control and Prevention (CDC): Knowledge and practices of obstetricians and gynecologists regarding cytomegalovirus infection during pregnancy - United States, 2007. MMWR Morb Mortal Wkly Rep 2008; 57: 65-68
23. Maidji E, Percivalle E, Gerna G, Fisher S, Pereira L: Transmission of human cytomegalovirus from infected uterine microvascular endothelial cells to differentiating/invasive placental cytotrophoblasts. Virology 2002; 304: 53-69
24. Maidji E, Nigro G, Tabata T, McDonagh S, Nozawa N, Shiboski S, Muci S, Anceschi MM, Aziz N, Adler SP, Pereira L: Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection. Am J Pathol 2010; 177: 1298-1310
25. Pereira L, Maidji E, McDonagh S, Genbacev O, Fisher S: Human cytomegalovirus transmission from the uterus to the placenta correlates with the presence of pathogenic bacteria and maternal immunity. J Virol 2003; 77: 13301-13314
26. Maidji E, McDonagh S, Genbacev O, Tabata T, Pereira L: Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 2006; 168: 1210-1226
27. Simister NE: Placental transport of immunoglobulin G. Vaccine 2003; 21: 3365-3369
28. Mussi-Pinhata MM, Pinto PC, Yamamoto AY, Berencsi K, De Souza CB, Andrea M, Duarte G, Jorge SM: Placental transfer of naturally acquired, maternal cytomegalovirus antibodies in term and preterm neonates. J Med Virol 2003; 69: 232-239
29. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H: Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996; 36: 248-255
30. Revello MG, Fabbri E, Furione M, Zavattoni M, Lilleri D, Tassis B, Quarenghi A, Cena C, Arossa A, Montanari L, Rognoni V, Spinillo A, Gerna G: Role of prenatal diagnosis and counseling in the management of 735 pregnancies complicated by primary human cytomegalovirus infection: a 20-year experience. J Clin Virol 2011; 50: 303-307
31. Feldman B, Yinon Y, Tepperberg Oikawa M, Yoeli R, Schiff E, Lipitz S: Pregestational, periconceptional, and gestational primary maternal cytomegalovirus infection: prenatal diagnosis in 508 pregnancies. Am J Obstet Gynecol 2011; 205: 342.e1-e6
32. Revello MG, Zavattoni M, Furione M, Lilleri D, Gorini G, Gerna G: Diagnosis and outcome of preconceptional and periconceptional primary human cytomegalovirus infections. J Infect Dis 2002; 186: 553-557
33. Picone O, Vauloup-Fellous C, Cordier AG, Guitton S, Senat MV, Fuchs F, Ayoubi JM, Grangeot Keros L, Benachi A: A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome. Prenat Diagn 2013; 33: 751-758
34. Revello MG, Zavattoni M, Furione M, Fabbri E, Gerna G: Preconceptional primary human cytomegalovirus infection and risk of congenital infection. J Infect Dis 2006; 193: 783-787
35. Ahlfors K, Forsgren M, Ivarsson SA, Harris S, Svanberg L: Congenital cytomegalovirus infection: on the relation between type and time of maternal infection and infant s symptoms. Scand J Infect Dis 1983; 15: 129-138
36. Lipitz S, Yinon Y, Malinger G, Yagel S, Levit L, Hoffman C, Rantzer R, Weisz B: Risk of cytomegalovirus-Associated sequelae in relation to time of infection and findings on prenatal imaging. Ultrasound Obstet Gynecol 2013; 41: 508-514
37. Mostoufi-Zadeh M, Driscoll SG, Biano SA, Kundsin RB: Placental evidence of cytomegalovirus infection of the fetus and neonate. Arch Pathol Lab Med 1984; 108: 403-406
38. La Torre R, Nigro G, Mazzocco M, Best AM, Adler SP: Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. Clin Infect Dis 2006; 43: 994-1000
39. Adler SP, Nigro G, Pereira L: Recent advances in the prevention and treatment of congenital cytomegalovirus infections. Semin Perinatol 2007; 31: 10-18
40. Gabrielli L, Bonasoni MP, Lazzarotto T, Lega S, Santini D, Foschini MP, Guerra B, Baccolini F, Piccirilli G, Chiereghin A, Petrisli E, Gardini G, Lanari M, Landini MP: Histological findings in foetuses congenitally infected by cytomegalovirus. J Clin Virol 2009; 46(suppl 4): S16-S21
41. Revello MG, Gerna G: Diagnosis and management of human cytomegalovirus infection in the mother, fetus and newborn infant. Clin Microbiol Rev 2002; 15: 680-715
42. Lazzarotto T, Guerra B, Gabrielli L, Lanari M, Landini MP: Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. Clin Microbiol Infect 2011; 17: 1285-1293
43. Pass RF, Griffiths PD, August AM: Antibody response to cytomegalovirus after renal transplantation: comparison of patients with primary and recurrent infections. J Infect Dis 1983; 147: 40-46
44. Guerra B, Simonazzi G, Puccetti C, Lanari M, Farina A, Lazzarotto T, Rizzo N: Ultrasound prediction of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol 2008; 198: 380.e1-e7
45. Benoist G, Salomon LJ, Mohlo M, Suarez B, Jacquemard F, Ville Y: Cytomegalovirus-related fetal brain lesions: comparison between targeted ultrasound examination and magnetic resonance imaging. Ultrasound Obstet Gynecol 2008; 32: 900-905
46. Nigro G, Adler SP, La Torre R, Best AM; Congenital Cytomegalovirus Collaborating Group: Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005; 353: 1350-1362
47. Goegebuer T, Van Meensel B, Beuselinck K, Cossey V, Van Ranst M, Hanssens M, Lagrou K: Clinical predictive value of real-time PCR quantification of human cytomegalovirus DNA in amniotic fluid samples. J Clin Microbiol 2009; 47: 660-665
48. Fabbri E, Revello MG, Furione M, Zavattoni M, Lilleri D, Tassis B, Quarenghi A, Rustico M, Nicolini U, Ferrazzi E, Gerna G: Prognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood. BJOG 2011; 118: 448-456
49. Romanelli RM, Magny JF, Jacquemard F: Prognostic markers of symptomatic congenital cytomegalovirus infection. Braz J Infect Dis 2008; 12: 38-43
50. Hall JM, Lingenfelter P, Adams SL, Lasser D, Hansen JA, Bean MA: Detection of maternal cells in human umbilical cord blood using fluorescence in situ hybridization. Blood 1995; 86: 2829-2832
51. Adler SP: Editorial commentary: Primary maternal cytomegalovirus infection during pregnancy: do we have a treatment option?. Clin Infect Dis 2012; 55: 504-506
52. Walker SP, Palma-Dias R, Wood EM, Shekleton P, Giles ML: Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy Childbirth 2013; 13: 96
53. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA: The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992; 326: 663-667
54. Ross SA, Fowler KB, Ashrith G, Stagno S, Britt WJ, Pass RF, Boppana SB: Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J Pediatr 2006; 148: 332-336
55. Boppana SB, Britt WJ: Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 1995; 171: 1115-1121
56. Freed DC, Tang Q, Tang A, Li F, He X, Huang Z, Meng W, Xia L, Finnefrock AC, Durr E, Espeseth AS, Casimiro DR, Zhang N, Shiver JW, Wang D, An Z, Fu TM: Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci U S A 2013; 110: E4997-E5005
57. Fouts AE, Comps-Agrar L, Stengel KF, Ellerman D, Schoeffler AJ, Warming S, Eaton DL, Feierbach B: Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. Proc Natl Acad Sci U S A 2014; 111: 8209-8214
58. Cui X, Meza BP, Adler SP, McVoy MA: Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008; 26: 5760-5766
59. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-755
60. Hoetzenecker K, Hacker S, Hoetzenecker W, Sadeghi K, Sachet M, Pollreisz A, Mangold A, Wliszczak T, Bielek E, Muehlbacher F, Klepetko W, Ankersmit HJ: Cytomegalovirus hyperimmunoglobulin: mechanisms in allo-immune response in vitro. Eur J Clin Invest 2007; 37: 978-986
61. Novaretti MC, Dinardo CL: Immunoglobulin: production, mechanisms of action and formulations. Rev Bras Hematol Hemoter 2011; 33: 377-382
62. Cekinovic D, Golemac M, Pugel EP, Tomac J, Cicin-Sain L, Slavuljica I, Bradford R, Misch S, Winkler TH, Mach M, Britt WJ, Jonjic S: Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J Virol 2008; 82: 12172-12180
63. Thürmann PA, Sonnenburg-Chatzopoulos C, Lissner R: Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation. Eur J Clin Pharmacol 1995; 49: 237-242
64. Buxmann H, Stackelberg OM, Schlöβer RL, Enders G, Gonser M, Meyer-Wittkopf M, Hamprecht K, Enders M: Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis. J Perinat Med 2012; 40: 439-446
65. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, Guaschino S, Vergani P, Todros T, Frusca T, Arossa A, Furione M, Rognoni V, Rizzo N, Gabrielli L, Klersy C, Gerna G; CHIP Study Group: A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 2014; 370: 1316-1326
66. Nigro G, La Torre R, Anceschi MM, Mazzocco M, Cosmi EV: Hyperimmunoglobulin therapy for a twin fetus with cytomegalovirus infection and growth restriction. Am J Obstet Gynecol 1999; 180: 1222-1226
67. Moxley K, Knudtson EJ: Resolution of hydrops secondary to cytomegalovirus after maternal and fetal treatment with human cytomegalovirus hyperimmune globulin. Obstet Gynecol 2008; 111: 524-526
68. Moise KJ, Wolfe H: Treatment of second trimester fetal cytomegalovirus infection with maternal hyperimmune globulin. Prenat Diagn 2008; 28: 264-265
69. Nigro G, La Torre R, Pentimalli H, Taverna P, Lituania M, De Tejada BM, Adler SP: Regression of fetal cerebral abnormalities by primary cytomegalovirus infection following hyperimmunoglobulin therapy. Prenat Diagn 2008; 28: 512-517
70. Nigro G, Adler SP, Gatta E, Mascaretti G, Megaloikonomou A, La Torre R, Necozione S: Fetal hyperechogenic bowel may indicate congenital cytomegalovirus disease responsive to immunoglobulin therapy. J Matern Fetal Neonatal Med 2012; 25: 2202-2205
71. Visentin S, Manara R, Milanese L, Da Roit A, Forner G, Salviato E, Citton V, Magno FM, Orzan E, Morando C, Cusinato R, Mengoli C, Palu G, Ermani M, Rinaldi R, Cosmi E, Gussetti N: Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis 2012; 55: 497-503
72. Nigro G, Adler SP, Parruti G, Anceschi MM, Coclite E, Pezone I, Di Renzo GC: Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy - A case-control study of the outcome in children. J Infect Dis 2012; 205: 215-227
73. Japanese Congenital Cytomegalovirus Infection Immunoglobulin Fetal Therapy Study Group: A trial of immunoglobulin fetal therapy for symptomatic congenital cytomegalovirus infection. J Reprod Immunol 2012; 95: 73-79
74. Yoshida M, Matsuda H, Hasegawa Y, Yoshinaga Y, Asai K, Kawashima A, Furuya K: Accumulation of fetal IgG in immunoglobulin injection into the fetal abdominal cavity is proven. Fetal Diagn Ther 2011; 29: 229-232
75. Kim SR, Won HS, Lee PR, Kim A: Four-dimensional ultrasound guidance of prenatal invasive procedures. Ultrasound Obstet Gynecol 2005; 26: 663-665
76. Buchacher A, Iberer G: Purification of intravenous immunoglobulin G from human plasma - Aspects of yield and virus safety. Biotechnol J 2006; 1: 148-163
77. Ballow M: Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38: 122-132
78. Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A, MacDonald S, Bailey AC: Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000; 78: 86-95
79. Carbone J: Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007; 2: 9-18
80. Hamrock DJ: Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6: 535-542
81. Orbach H, Katz U, Sherer Y, Shoenfeld Y: Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29: 173-184
82. Rachid R, Bonilla FA: The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012; 129: 628-634
83. Nigro G, Capretti I, Manganello AM, Best AM, Adler SP: Primary maternal cytomegalovirus infections during pregnancy: association of CMV hyperimmune globulin with gestational age at birth and birth weight. J Matern Fetal Neonatal Med 2015; 28: 168-171
84. Fu TM, An Z, Wang D: Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine 2014; 32: 2525-2533
85. Stern H, Tucker SM: Cytomegalovirus infection in the newborn and in early childhood. Three atypical cases. Lancet 1965; 2: 1268-1271